By Dave Sebastian

 

Merck & Co. Inc. (MRK) said Wednesday the U.S. Food and Drug Administration has approved its Recarbrio drug injection for urinary-tract and intra-abdominal bacterial infections.

The New Jersey pharmaceutical company said it anticipates to make Recarbrio available later this year.

The drug is a combination of imipenem and cilastatin--both antibacterial components--as well as relebactam, which protects imipenem from certain enzymes, Merck said.

Relebactam received the FDA's Qualified Infectious Disease Product designation for the treatment of complicated urinary tract and complicated intra-abdominal bacterial infections, and the FDA gave Recarbrio's drug application a priority-review designation, the company said.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

July 17, 2019 07:30 ET (11:30 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Merck
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Merck